

Complete scintigraphic resolution of a bone metastasis after androgen-deprivation therapy

Androjen-Deprivasyon tedavisi ile regrese olan kemik metastazının sintigrafik değerlendirmesi

Derya Çayır¹, Mehmet Bozkurt¹, Salih Sinan Gültekin¹, Aynur Turan²

¹ University of Health Sciences, Dışkapı Yıldırım Beyazıt Training and Research Hospital, Nuclear Medicine Department, Ankara, Turkey

² University of Health Sciences Dışkapı Yıldırım Beyazıt Training and Research Hospital, Radiology Department, Ankara, Turkey

ORCID ID of the author(s)

DC: 0000-0002-7756-3210

MB: 0000-0002-8325-5249

SSG: 0000-0003-2458-3530

AT: 0000-0001-6654-3129

Abstract

^{99m}Tc-methylene diphosphonate (MDP) whole body bone scintigraphy is a frequently used imaging method for the evaluation of the bone metastases of prostate cancer. Nuclear medicine imaging modalities are very valuable in terms of functional assessment and treatment response assessment of the malign lesions that cannot be detected by anatomic imaging methods. However, it is known that some scintigraphic studies may have a relatively limited role in defining resolution and anatomical details of the lesion, compared to some radiological imaging modalities. Androgen-deprivation therapy (ADT) alone is rarely effective for the treatment of bone metastases, on that account combined systemic therapies are often preferred. Here we present a rare case of prostate cancer with radiologically undetectable bone metastasis evident on scintigraphy that has disappeared after 18 months of ADT.

Keywords: Whole body scan, Prostate cancer, Metastasis, Tomography

Öz

^{99m}Tc-metilen difosfonat (MDP) tüm vücut kemik sintigrafisi prostat kanserinin kemik metastazlarını değerlendirmede sıklıkla kullanılmaktadır. Anatomi görüntüleme yöntemleri ile saptanamayan malign lezyonların fonksiyonel olarak izlenebilmesi ve tedaviye yanıtının değerlendirilebilmesi açısından nükleer tıp tetkikleri çok değerlidir. Bununla birlikte sintigrafik yöntemlerin rezolüsyon ve anatomik detayları belirlemede bazı radyolojik tetkiklere göre sınırlı olabildiği bilinmektedir. Kemik metastazlarının tedavisinde sıklıkla kombine sistemik tedaviler tercih edilmekte olup, androjen-deprivasyon tedavisi (ADT) tek başına nadiren etkilidir. Burada bilgisayarlı tomografi ile saptanamayan, 18 ay ADT ile regrese olan kemik metastazlı nadir prostat kanserli bir olguyu sunuyoruz.

Anahtar kelimeler: Tüm vücut görüntüleme, Prostat kanseri, Metastaz, Tomografi

Introduction

The most common indication of ^{99m}Tc-MDP bone scintigraphy is to detect osteoblastic bone metastases of various malignities. It is cost-effective, accessible, without known contraindications, and highly sensitive [1]. Since metabolic changes in bone show up earlier than anatomical changes, bone scintigraphy may detect bone pathologies sooner than anatomic imaging modalities [2]. We herein present a case with prostate cancer who had a radiologically undetectable bone metastasis evident on scintigraphy which disappeared after androgen-deprivation therapy (ADT).

Corresponding author / Sorumlu yazar:

Derya Çayır

Address / Adres: Sağlık Bilimleri Üniversitesi Dışkapı Yıldırım Beyazıt Eğitim ve Araştırma Hastanesi, Nükleer Tıp Bölümü, 06110, Ankara, Türkiye

e-Mail: drderyaors@hotmail.com

Informed Consent: The authors stated that the written consent was obtained from the patient presented with images in the study.

Hasta Onamı: Yazar çalışmada görüntüleri sunulan hastadan yazılı onam alındığını ifade etmiştir.

Conflict of Interest: No conflict of interest was declared by the authors.

Çıkar Çatışması: Yazarlar çıkar çatışması bildirmemişlerdir.

Financial Disclosure: The authors declared that this study has received no financial support. Finansal Destek: Yazarlar bu çalışma için finansal destek almadıklarını beyan etmişlerdir.

This study was accepted as an e-poster at the 30th Annual National Congress of Turkish Association of Nuclear Medicine, April 2018, Antalya, Turkey.

Published: 12/28/2019

Yayın Tarihi: 28.12.2019

Copyright © 2019 The Author(s)

Published by JOSAM

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-NoDerivatives License 4.0 (CC BY-NC-ND 4.0) where it is permissible to download, share, remix, transform, and build up the work provided it is properly cited. The work cannot be used commercially without permission from the journal.



Case presentation

A 68 year-old male patient diagnosed with prostate adenocarcinoma (Gleason score 4 + 5) was admitted to our department. He presented with high serum prostate-specific antigen level [PSA): 43.17 ng/mL (N:0-4)]. ^{99m}Tc -MDP in whole-body bone scintigraphy and Single Photon Emission Computed Tomography (SPECT) imaging revealed a focal activity in the coccygeal area (Figure 1). Computed tomography (CT) was performed for accurate differential diagnosis of possible sacrum fractures. Trauma history was insistently questioned, no history of trauma was evident in anamnesis. There was no significant finding on CT, except for degenerative changes in the sacroiliac region (Figure 2). ADT was initiated after the diagnosis of sacral metastasis. After 18 months of treatment, serum PSA level decreased to 1.1 ng/mL, and the ^{99m}Tc -MDP whole body bone scintigraphy revealed no lesions in the coccygeal area (Figure 3). A written informed consent was obtained from the patient.




Figure 1: ^{99m}Tc -MDP in whole-body bone scintigraphy (A) and Single Photon Emission Computed Tomography (SPECT) (B) imaging showed a focal activity in the coccygeal area (arrows)




Figure 2: Computed tomography (CT) revealed no significant finding except degenerative changes in the sacroiliac region (A; sagittal plane, B; transaxial plane, arrows).



Figure 3: ^{99m}Tc -MDP whole body bone scintigraphy revealed no lesion in the coccygeal area

Discussion

Prostate cancer is the most common malignancy in elderly men [3]. Ordinarily, the skeletal system is the most frequent target of metastases in castration-resistant prostate cancer, with an estimate of involvement around 90% [4]. On account of suspected bone metastases, high PSA level is an important, widely available serum marker. A serum PSA level above 10 ng/ml, and/or a Gleason score above 8 should prompt investigation for bone metastases [5]. Radiologic imaging modalities, such as CT and magnetic resonance imaging (MRI) provide structural and anatomical details of the bone. Nevertheless, the results are more significant whenever the anatomical imaging methods and the functional evaluation tests are correlated. Surgical castration with subsequent androgen-deprivation therapy (ADT) has been favored for treatment of metastatic prostate cancer since the 1940s [6]. The treatment of bone metastases of prostate cancer includes bisphosphonates, radiotherapy, chemotherapy, hormone therapy, surgery, radionuclide therapy, immunotherapy, and palliative treatments [7]. Antiandrogen therapies (such as bicalutamide, flutamide, nilutamide, and enzalutamide) alone are mainly used in locally advanced prostate cancer, however, they are rarely effective for treating bone metastases of prostate cancer [8]. Our patient received bicalutamide 50 mg/day after the diagnosis of sacral metastasis. At the end of 18 months of treatment, his PSA levels had decreased, and bone scintigraphy showed no radioactivity uptake in the pelvic area, consistent with a complete resolution of the bone metastasis.

^{99m}Tc -MDP whole body bone scintigraphy has advantages over other anatomical imaging modalities regarding the functional evaluation of new bone metastases and the progression or response assessment of previously diagnosed bone metastases in patients with prostate cancer. Therefore, in asymptomatic patients with prostate cancer and high serum PSA levels, bone scintigraphy might play a role in identifying metastatic lesions, despite normal findings on anatomic studies.

References

1. Van den Wyngaert T, Strobel K, Kampen WU, Van den Wyngaert T, Strobel K, Kampen WU, et al. The EANM practice guidelines for bone scintigraphy. *Eur J Nucl Med Mol Imaging*. 2016;43:1723-38.
2. Bozkurt MF, Dede Z, Burak Z, Ak I, Bekis R, Degirmenci B, et al. Procedure Guideline For Bone Scintigraphy. *Turk J Nucl Med*. 2001;10:97-102.
3. K l k ci E, Beyhan M, Atilgan D. Factors affecting complications of transrectal ultrasound-guided prostate biopsy: A cohort study with 403 patients in a single center. *J Surg Med*. 2019;3(2):183-6.
4. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. *CA Cancer J Clin*. 2010;60:277-300.
5. O'Sullivan JM, Norman AR, Cook GJ, Fisher C, Dearnaley DP. Broadening the criteria for avoiding staging bone scans in prostate cancer: a retrospective study of patients at the Royal Marsden Hospital. *BJU Int*. 2003;92:685-9.
6. Huggins C, Hodges CV. Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. *Cancer Res*. 1941;1:293-7.
7. Cornford P, Bellmunt J, Bolla M, Briers E, De Santis M, Gross T, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. *Eur Urol*. 2017;71:630-42.
8. Mcleod DG, Iversen P, See WA, Morris T, Armstrong J, Wirth MP, et al. Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer. *BJU International*. 2006;97:247-54.

This paper has been checked for language accuracy by JOSAM editors.

The National Library of Medicine (NLM) citation style guide has been used in this paper.

Suggested citation: Patrias K. Citing medicine: the NLM style guide for authors, editors, and publishers [Internet]. 2nd ed. Wendling DL, technical editor. Bethesda (MD): National Library of Medicine (US); 2007-[updated 2015 Oct 2; cited Year Month Day]. Available from: <http://www.nlm.nih.gov/citingmedicine>